AI Alliance Targets Cancer Using Vast Tumor Biobank
Pittsburgh, Wednesday, 18 November 2026.
DiaGen AI and Helomics are deploying machine learning across 70,000 tumor biopsies to develop therapies, beginning with cancer-fighting peptides demonstrated to be 5.5 times less toxic to healthy blood cells.
Strategic Partnership Announced on November 18, 2026
On November 18, 2026, DataMeds AI (NASDAQ: MEDS) announced through its subsidiary Helomics, Inc. a strategic partnership with DiaGen AI, Inc., a Vancouver-based AI-driven drug discovery firm [1][2]. The collaboration aims to leverage Helomics’ repository of over 70,000 primary tumor samples—including the world’s largest gynecologic cancer biopsy collection—to accelerate oncology drug discovery [1][2]. DiaGen AI will deploy its CYPRESS platform to validate 15 anticancer peptides initially demonstrated to exhibit 5.5 times lower toxicity to normal human blood cells compared to cancer cells in vitro [1][2].
Scientific Foundation and Initial Breakthroughs
The partnership’s scientific underpinning stems from research co-authored by DiaGen AI’s Chief AI Officer, Mohit Pandey, Ph.D., published in Nature Communications [1]. The validated peptides, identified via DiaGen’s CYPRESS platform, have demonstrated in vitro proof-of-concept in breast cancer cell lines, including triple-negative breast cancer [1][2]. Dr. Pandey emphasized the transformative potential of accessing Helomics’ biobank alongside proprietary AI tools like the BLACKCOMB platform for designing drug candidates: ‘Being able to access this robust primary tumor biobank and Helomics’ proprietary capabilities to identify new therapeutic targets… is a transformative opportunity for DiaGen’ [1].
Collaboration Structure and Financial Terms
The agreement includes a share exchange where DataMeds will issue 630,000 common shares (9.9% of outstanding shares) to DiaGen AI, and DiaGen will issue 9.9% of its fully diluted shares to DataMeds [1][2]. The total transaction value is set at $1.5 million, combining cash and in-kind contributions, with Helomics contributing up to 50% of compute expenses and DiaGen funding wet lab experiments [1][2]. Gerald Commissiong, Interim Co-CEO of DataMeds AI, highlighted the monetization potential of Helomics’ biobank: ‘We are excited to have identified our first partner that begins the process of monetizing the unique resources in our lab…’ [1].
Expansion Plans and Future Milestones
Beyond breast cancer, the partnership plans to expand screening into gastrointestinal, brain, lung, pancreatic, ovarian, and other tumor types within Helomics’ biobank, which spans over 130 cancer types [1][2][alert! ‘Timeline for expansion not explicitly stated’]. The collaboration aims to achieve animal proof-of-concept in breast cancer models and in vitro validation across up to 13 cancer types, with joint intellectual property ownership for discoveries made [1][2]. If successful, the companies intend to partner resulting candidates with pharmaceutical firms or form a joint venture for further development [1][2][alert! ‘No explicit timeline provided for partnership formation’].
Helomics’ Role in Precision Oncology
Helomics operates as a CLIA-certified clinical laboratory under DataMeds AI, specializing in precision oncology through its proprietary ChemoFx® Assay (CPT codes 81535 and 81536) and Cancer Biomarker Super Intelligence division [1]. The division integrates an annotated biobank of tumor samples with AI and multi-omic data to drive therapeutic discovery [1]. Helomics’ 3D tumor spheroid testing and cell painting capabilities will complement DiaGen’s AI-driven drug design platforms [1][2]. The partnership aligns with Helomics’ broader goal of unlocking value from its curated biobank while advancing early-stage drug validation [1].